Sarepta Therapeutics | SRPT - 应收帐款人



金融业
股票价格
USD
资产
USD 3.35B
现金及等价物
USD 801.28M
销售成本
USD 399.39M
流动资产
USD 2.54B
流动负债
USD 1.1B
债务
USD 1.25B
EBIT
USD -410.08M
EBITDA
USD -168.03M
员工
1.37K
EPS每股收益
USD -3.58
股本和储备
USD 1.14B
销售毛利
USD 43.55M
债务利息支出
USD 7.56M
利息收入
USD 8.38M
贷款资金
USD 828.97M
市值
USD 2.07B
净收入
USD -412.23M
营业费用
USD 853.02M
营业利润
USD -410.08M
普通股股本
USD 104.96M
PE价格收益
27.27
税前利润
USD -407.68M
销售收入
USD 442.9M
销售和管理费用
USD 105.38M
股票
USD 914.74M
贸易债权人
USD 280.84M
应收帐款人
USD 398.23M


应收帐款人 更改 日
Acadia Pharmaceuticals USD 148.23M 8.79M 2025-12
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
Alnylam Pharmaceuticals USD 883.96M 106.39M 2026-03
Amgen USD 9.14B 432M 2026-03
BioCryst Pharmaceuticals USD 106.82M 15.49M 2025-12
Biogen USD 1.79B 76.6M 2026-03
BioMarin Pharmaceutical USD 903.91M 4.3M 2026-03
Capricor Therapeutics USD 59K 0 2025-12
Daiichi Sankyo JPY 695.95B 79.1B 2025-12
Eli Lilly USD 21.18B 1.02B 2026-03
Esperion Therapeutics USD 140.19M 21.21M 2025-12
Gilead Sciences USD 4.91B 182M 2025-12
Incyte USD 1.05B 27.09M 2026-03
Insmed USD 140.86M 75.6M 2025-12
Ionis Pharmaceuticals USD 74M 8M 2026-03
Moderna USD 71M 113M 2026-03
Nektar Therapeutics USD 1.78M 1.12M 2025-12
Neurocrine Biosciences USD 686.8M 41.2M 2025-12
Novavax USD 106.45M 72.27M 2025-12
Pfizer USD 15.84B 2.27B 2025-12
PTC Therapeutics USD 181.62M 21.45M 2025-12
Regeneron Pharmaceuticals USD 5.73B 10.1M 2026-03
Roche Holding CHF 11.9B 460M 2025-12
Sangamo BioSciences USD 581K 110K 2024-06
Sanofi EUR 482M 85M 2026-03
Sarepta Therapeutics USD 398.23M 2.49M 2025-12
Tectonic Therapeutic USD 0 270K 2023-12
Ultragenyx Pharmaceutical USD 158M 45.46M 2025-12
Vertex Pharmaceuticals USD 2B 56.7M 2026-03